Nonmelanoma skin cancers (NMSC), which account for at least 30% of all cancer diagnoses, are an increasing health burden. Approximately 5 million adults are treated in the United States each year for basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (CSCC), and the incidence of these cancers is increasing globally. Although they are treatable with surgery or radiotherapy, locally advanced or metastatic forms of these carcinomas are life-threatening, difficult to treat, not amenable to those standard options, and historically have had few treatment options.
Greater knowledge of the role of the immune system in the development of cancer, and of the role of programmed death-1 (PD-1) in evading immune clearance, has led to the study of PD-1 and PD-L1 inhibitors in the management of advanced and metastatic NMSCs. This research has led to the approval of a checkpoint inhibitor as the first treatment specifically for advanced CSCC and the continued development of checkpoint inhibitors for treating advanced BCC. Oncologists need to be aware of what constitutes a thorough diagnostic evaluation and accurate staging of patients to develop more effective individualized, evidence-based management plans. In addition, oncologists need to understand current evidence regarding the use of immunotherapies such as checkpoint inhibitors.
To meet these needs, Rockpointe and the Potomac Center for Medical Education offer a free CME/ANCC/MOC/MIPS activity geared toward oncologists, oncology nurses, and other clinicians who are responsible for the diagnosis and management of patients with advanced NMSC. Nonmelanoma Skin Cancers: Current and Emerging Checkpoint Inhibitors for Treating Advanced Basal Cell and Squamous Cell Carcinomas will provide oncologists with current guideline-based diagnostic, staging, and treatment strategies for patients with advanced BCC and CSCC, and will discuss how newly approved agents in development fit into treatment strategies.
This hour-long program is available in live and enduring formats. Live virtual presentations are scheduled at regional American Society of Clinical Oncology (ASCO) meeting on December 9, 2021, and during a series of in-hospital virtual grand rounds as follows:
Dates and times
Monday, November 8, 2021
1:30 – 2:30 PM ET (12:30 – 1:30 PM CT / 10:30 – 11:30 AM PT)
Wednesday, November 10, 2021
8:00 – 9:00 AM ET (7:00 AM – 8:00 AM CT / 5:00 – 6:00 AM PT)
For those who are unable to attend the live virtual presentations, an enduring webcourse available until August 18, 2022, will allow clinicians to participate in the activity at their convenience.
This free educational initiative is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine. At the program’s conclusion, participants should be able to:
- Make timely diagnoses of patients with BCC or CSCC using current evidence-based criteria.
- Accurately stage and risk-stratify patients with BCC or CSCC to establish optimal follow-up regimens.
- Make evidence-based treatment selections for patients with advanced BCC or CSCC.
- Assess the safety and efficacy of emerging therapies for advanced BCC or CSCC.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education (PCME), Rockpointe, and Amedco LLC. PCME, which is accredited by the ACCME to provide continuing medical education for physicians, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
Amedco LLC is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Amedco designates this activity for a maximum of 1 ANCC contact hour.
Successful completion of this CME program, which includes participation in the evaluation component, enables participants to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.
Completion of this accredited CME activity also meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).
There is no fee for this activity, which is supported by an independent medical education grant from Regeneron Pharmaceuticals and Sanofi Genzyme. To receive credit, participants must register, view the CME activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.
Through effective continuing medical education, Rockpointe strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MIPS, combatting the nation’s opioid and COVID-19 crises, recognizing issues with vaping, and utilizing technical advances in care. As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy & Medicine, which offers a daily look at legal, regulatory, and compliance issues affecting the pharmaceutical and device industry. Rockpointe also publishes Policy & Medicine Compliance Update, a monthly publication that provides a concise update on compliance issues facing the life science industry and goes in-depth into important cases, laws, and regulations in straightforward articles. At Rockpointe, education equals quality.
To register for the enduring webcourse, click here. To register for one of the live virtual grand rounds sessions, click here. To register for the December 9 ASCO session, click here.